Cognition Therapeutics, Inc. · NASDAQ:CGTX
Cognition Therapeutics — Investor Presentation (March 2026)
31 slides from Cognition Therapeutics's investor presentation, March 2026
Slide 1: Zervimesine: a Once-daily Oral Therapeutic Advancing Toward Phase 3
Zervimesine: a Once-daily Oral Therapeutic Advancing Toward Phase 3 March 2026
Slide 2: Forward-looking Statements
Forward-looking Statements FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts or statements that relate t
Slide 3: Presentation Roadmap
Presentation Roadmap Corporate DLB Alzheimer’s Geographic Financials Introduction Psychosis Disease Atrophy • Executive summary • Phase 2 results • Phase 2 results in • Phase 2 results • Summary mild-mod AD • Zervimesine MoA • Neuropsychiatric • Comparison to • Financials signals with no • p-tau217
Slide 4: Over $170M in grants from NIH & others substantially funded development through Phase 2
Over $170M in grants from NIH & others substantially funded development through Phase 2 • Potential first-to-market for DLB psychosis - Majority of DLB patients experience psychosis - Psychotic symptoms result in higher HC costs and institutionalization - No drugs approved; off label use limited by
Slide 5: Zervimesine (CT1812) – Lead Product Candidate
Zervimesine (CT1812) – Lead Product Candidate BBB-penetrant small molecule oligomer antagonist • Zervimesine binds to TMEM97 (sigma-2) receptor MoA: Protecting neurons from toxic oligomers Zervimesine • Oral, once-daily dosing PrPc • Favorable safety profile consistent through lilrb2 TMEM97 multiple
Slide 6: Findings from Completed Studies Support Phase 3 Plans
Findings from Completed Studies Support Phase 3 Plans Patient Population Program Treatment Takeaways from completed studies period Ongoing Studies • Phase 2 SHINE Study: efficacy across Alzheimer’s disease Phase 2 COG0203 • START 18 months cognitive measures; particularly robust MCI and Early respon
Slide 7: Prioritizing DLB Psychosis Following Regulatory Feedback
Prioritizing DLB Psychosis Following Regulatory Feedback Completed FDA meetings complete with feedback on AD and DLB clinical programs Completed: Type C Meeting for DLB Completed: AD End-of-Phase 2 Meeting • Focused on clinical outcomes that encompass • Aligned with FDA on following: DLB’s complex s
Slide 8: Dementia with Lewy Bodies (DLB) Psychosis
Dementia with Lewy Bodies (DLB) Psychosis Addressing unmet need of majority of DLB patients
Slide 9: Four Core Domains + Functional Impairment Drive DLB Burden
Four Core Domains + Functional Impairment Drive DLB Burden DLB is “a multifactorial disease with a buffet of symptoms” James E. Galvin, MD, MPH, Univ Miami Miller School of Medicine Behavior Cognition Fluctuations Movement Function Diminished Impaired memory Difficulty standing, Patient Hallucinatio
Slide 10: Complex Symptomology Requires Array of Assessments
Complex Symptomology Requires Array of Assessments All assessments are standardized and have been used in clinical trials and drug approvals Assessment tools measure a variety of symptoms Behavior Cognition Fluctuations Movement Function Cognitive Drug Clinician MDS-Unified PD ADCS-Activities Neurop
Slide 11: Phase 2 Study in Dementia with Lewy Bodies
Phase 2 Study in Dementia with Lewy Bodies Funded by $30M NIA grant (R01AG071643) Enrollment Treatment Period Program Assessments Criteria 6 months Objectives ‐ Age 50-85 ‐ Safety/tolerability Identify efficacy Zervimesine 300 mg 130 ‐ Behavior - NPI signal(s) ‐ DLB diagnosis participants ‐ Cognit
Slide 12: Up to 91% Percent Slowing on Assessments
Up to 91% Percent Slowing on Assessments Strong clinical signals across major DLB symptoms relative to placebo Behavior Cognition Fluctuations Movement Function Cognitive Drug Clinician MDS-Unified PD ADCS-Activities Neuropsychiatric Assessment Inventory (NPI) 86% Research (CDR) System 86% Assessmen
Slide 13: Zervimesine-Dramatic 86% Impact on Neuropsychiatric Measures
Zervimesine-Dramatic 86% Impact on Neuropsychiatric Measures NPI captures broad number of patient disturbances, including hallucinations, anxiety, and delusions NPI NPI favor Treatment with Zervimesine NPI Total Score (A-L) 86% Slowing LS Mean Difference from Placebo 95% CI Anxiety Delusions Halluci
Slide 14: Because Participants Improved in Hallucinations, Delusions & Anxiety, Caregivers Reported Less Distress
Because Participants Improved in Hallucinations, Delusions & Anxiety, Caregivers Reported Less Distress Companion tool to measure caregiver distress based on neuropsychiatric symptoms NPI Distress NPI Distress favors Treatment with Zervimesine NPI Total Score (A-L) Caregiver Distress 114% Slowing LS
Slide 15: Zervimesine Stabilizes Psychotic and Behavioral Symptoms
Zervimesine Stabilizes Psychotic and Behavioral Symptoms Evaluating NPI-4 as the endpoint for psychotic and behavioral symptoms NPI-4 (All Participants) 102% Slowing • The NPI-4 assesses the core psychosis symptoms of hallucinations and delusions plus behavioral symptoms including anxiety and P vs p
Slide 16: DLB Expanded Access Program (COG1202)
DLB Expanded Access Program (COG1202) Funded by an anonymous donation from SHIMMER family Program Period Program Enrollment Criteria 12 months Objectives ‐ Age 50-85 Long-term safety 32 participants ‐ DLB diagnosis Open Zervimesine 100 mg enrolled at 8 Continued access to Label U.S. sites medica
Slide 17: Zervimesine Making an Impact for DLB Patients
Zervimesine Making an Impact for DLB Patients Participant from Phase 2 and EAP comments on his experience with zervimesine in SHIMMER For years, Susan would order for me at restaurants because I couldn't put In the mornings he would stand sentences together. Now, I can order on my there and forget w
Slide 18: Regulatory Next Steps
Regulatory Next Steps New IND required to transition to FDA Division of Psychiatry • Meeting mid-May 2026; minutes June 2026 • Finalized registrational plan to follow • Randomization 1:1 zervimesine (100mg) : placebo • Endpoints are validated and have previously supported FDA approvals • Open-label
Slide 19: Alzheimer's Disease
Alzheimer’s Disease 95% slowing of cognitive decline in lower-p-tau217 'SHINE' participants
Slide 20: AD and DLB: Two Diseases with Overlapping Pathology
AD and DLB: Two Diseases with Overlapping Pathology Primary treatment goal is to slow the progression of disease • Aβ: associated with Alzheimer’s pathogenesis Amyloid • α-synuclein: associated with Lewy body dementias beta (Aβ) • Co-pathology is common - Up to 80% of DLB patients have BOTH α-synucl
Slide 21: Phase 2 PoC in Mild-to-Moderate Alzheimer's Disease
Phase 2 PoC in Mild-to-Moderate Alzheimer’s Disease Well-executed, over-enrolled study, supports advancing clinical development Treatment Period Enrollment Criteria Assessments 6 months Zervimesine 300 mg ‐ Safety/tolerability ‐ AD diagnosis confirmed by PET or CSF amyloid positivity* 153 participan
Slide 22: Up to 108% Slowing on Assessments in Lower p-Tau Population
Up to 108% Slowing on Assessments in Lower p-Tau Population Response of 100 and 300 mg dose groups are similar Cognition Function ADAS-Cog 11 ADAS-Cog 13 MMSE ADCS-ADL ADCS-CGIC median p-tau217 95% 103% 108% 68% 61% Endpoints measured 100/300mg zervimesine pooled vs placebo 23
Slide 23: Plasma p-Tau217: a Predictive Biomarker of Treatment Response
Plasma p-Tau217: a Predictive Biomarker of Treatment Response Plasma p-tau217 level correlates to degree of Alzheimer’s pathology • Individuals with lower levels of plasma p-tau217 at baseline have lower AD pathology. They show a greater response to amyloid- Increasing Levels of based therapies: Pla
Slide 24: Participants with Below Median p-Tau217 Experienced Profound Treatment Effect
Participants with Below Median p-Tau217 Experienced Profound Treatment Effect Successful end-of-Phase 2 meeting was based on these results ADAS-Cog 11* mITT population (n=150) Below median p-tau217 (n=69) Population selected for Phase 3 26 † Median plasma p-tau217 level is 1.0pg/mL at baseline
Slide 25: Consistent Treatment Impact in Participants with Lower p-Tau217 Across Baseline MMSE scores
Consistent Treatment Impact in Participants with Lower p-Tau217 Across Baseline MMSE scores Confirmed enrichment strategy and severity range at end-of-Phase 2 FDA meeting Zervimesine-treated Mild (MMSE 22-26) Participants Zervimesine-treated Moderate (MMSE 18-21) Participants 27
Slide 26: Consistent Safety Profile Across Completed Phase 2 Studies
Consistent Safety Profile Across Completed Phase 2 Studies Well tolerated in 271 participants with AD, DLB, dry AMD • Average age was ~75 years • Adverse events (AEs) were well balanced between treatment and placebo arms - Serious AEs occurred at comparable or higher rates in placebo- compared to ze
Slide 27: Phase 2 MCI and Early Alzheimer's Study
Phase 2 MCI and Early Alzheimer’s Study First study to allow approved mAbs as background therapy in combination with zervimesine Enrollment Treatment Period Program Assessments Criteria 18 months Objectives ‐ Ages 50-85 ‐ Safety Identify efficacy Zervimesine 200 mg signal(s) ‐ Diagnosis of MCI due
Slide 28: START Study Completed Enrollment 4Q 2025
START Study Completed Enrollment 4Q 2025 Groundbreaking ability to test combination with mABs • Enrollment complete (n=545) - First participant enrolled February 2024 - Last participant enrolled in December 2025 • Cognitive and functional testing: CDR-SB, ADAS-Cog 13, ADCS-ADL-MCI • Trial duration:
Slide 29: 3 Major Diseases Addressed with Once-Daily Oral Pill
3 Major Diseases Addressed with Once-Daily Oral Pill Collective Phase 2 results support advancing zervimesine (CT1812) to registrational studies Dementia with Alzheimer’s Disease Geographic Atrophy Lewy Bodies Marked slowing of progression Slowing of progression; robust Slowing of GA growth across m
Slide 30: Current Financial Position
Current Financial Position Cash runway through 2Q 2027 As of December 31, 2025 Cash, cash equivalents, and restricted cash equivalents $ 37 M Grant funding for zervimesine studies Preclinical through Phase 2 ~$171 M Approximate funding used ($135 M) Remaining grant funding $36 M 32
Slide 31: Thank You
Thank You Lisa Ricciardi President & CEO info@cogrx.com
Cognition Therapeutics — Investor Presentation (March 2026) on 6ix